Assay for Evaluation of Proarrhythmic Effects of Herbal Products: Case Study with 12 Preparations

Overview

Journal Toxicol Rep

Date 2023 May 22

PMID 37213814

Authors

Bozhidar Baltov

Stanislav Beyl

Igor Baburin

Jakob Reinhardt

Phillip Szkokan

Aleksandra Garifulina

Eugen Timin

Udo Kraushaar

Olivier Potterat

Matthias Hamburger

Philipp Kugler

Steffen Hering

Affiliations

Soon will be listed here.

Abstract

Guidelines for preclinical drug development reduce the occurrence of arrhythmia-related side effects. Besides ample evidence for the presence of arrhythmogenic substances in plants, there is no consensus on a research strategy for the evaluation of proarrhythmic effects of herbal products. Here, we propose a cardiac safety assay for the detection of proarrhythmic effects of plant extracts based on the experimental approaches described in the Comprehensive Proarrhythmia Assay (CiPA). Microelectrode array studies (MEAs) and voltage sensing optical technique on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were combined with ionic current measurements in mammalian cell lines simulations of cardiac action potentials (APs) and statistic regression analysis. Proarrhythmic effects of 12 preparations, containing different amounts of the hERG inhibitors dehydroevodiamine (DHE) and hortiamine were analysed. Extracts produced different prolongation of the AP, occurrence of early after depolarisations and triangulation of the AP in hiPSC-CMs depending on the contents of the hERG inhibitors. DHE and hortiamine dose-dependently prolonged the field potential duration in hiPSC-CMs studied with MEAs. simulations of ventricular AP support a scenario where proarrhythmic effects of extracts are predominantly caused by the content of the selective hERG inhibitors. Statistic regression analysis revealed a high torsadogenic risk for both compounds that was comparable to drugs assigned to the high-risk category in a CiPA study.

References

Kernik D, Morotti S, Wu H, Garg P, Duff H, Kurokawa J . A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. J Physiol. 2019; 597(17):4533-4564. PMC: 6767694. DOI: 10.1113/JP277724. View

Qian P, Zhang Y, Yang Y, Xu W, Yang X . Pharmacokinetics Studies of 12 Alkaloids in Rat Plasma after Oral Administration of Zuojin and Fan-Zuojin Formulas. Molecules. 2017; 22(2). PMC: 6155683. DOI: 10.3390/molecules22020214. View

Shih Y, Tsai C, Li T, Yu C, Chou J, Feng C . Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial. Phytomedicine. 2019; 56:118-125. DOI: 10.1016/j.phymed.2018.09.185. View

Liang X, Li B, Wu F, Li T, Wang Y, Ma Q . Bitterness and antibacterial activities of constituents from Evodia rutaecarpa. BMC Complement Altern Med. 2017; 17(1):180. PMC: 5372309. DOI: 10.1186/s12906-017-1701-8. View

Baburin I, Varkevisser R, Schramm A, Saxena P, Beyl S, Szkokan P . Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are I blockers with proarrhythmic effects in vitro and in vivo. Pharmacol Res. 2018; 131:150-163. DOI: 10.1016/j.phrs.2018.02.024. View

Kratz J, Grienke U, Scheel O, Mann S, Rollinger J . Natural products modulating the hERG channel: heartaches and hope. Nat Prod Rep. 2017; 34(8):957-980. PMC: 5708533. DOI: 10.1039/c7np00014f. View

Potterat O, Hamburger M . Concepts and technologies for tracking bioactive compounds in natural product extracts: generation of libraries, and hyphenation of analytical processes with bioassays. Nat Prod Rep. 2013; 30(4):546-64. DOI: 10.1039/c3np20094a. View

Millard D, Dang Q, Shi H, Zhang X, Strock C, Kraushaar U . Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study. Toxicol Sci. 2018; 164(2):550-562. PMC: 6061700. DOI: 10.1093/toxsci/kfy110. View

Kramer J, Obejero-Paz C, Myatt G, Kuryshev Y, Bruening-Wright A, Verducci J . MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep. 2013; 3:2100. PMC: 3696896. DOI: 10.1038/srep02100. View

10.

Hamburger M . HPLC-based activity profiling for pharmacologically and toxicologically relevant natural products - principles and recent examples. Pharm Biol. 2019; 57(1):328-334. PMC: 6507960. DOI: 10.1080/13880209.2019.1606261. View

11.

SELZER A, WRAY H . QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS. Circulation. 1964; 30:17-26. DOI: 10.1161/01.cir.30.1.17. View

12.

Patel D, Stohlman J, Dang Q, Strauss D, Blinova K . Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci. 2019; 170(1):167-179. DOI: 10.1093/toxsci/kfz076. View

13.

Schramm A, Hamburger M . Gram-scale purification of dehydroevodiamine from Evodia rutaecarpa fruits, and a procedure for selective removal of quaternary indoloquinazoline alkaloids from Evodia extracts. Fitoterapia. 2014; 94:127-33. DOI: 10.1016/j.fitote.2014.02.005. View

14.

Li M, Wang C . Traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the fruit of Tetradium ruticarpum: A review. J Ethnopharmacol. 2020; 263:113231. DOI: 10.1016/j.jep.2020.113231. View

15.

Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L . International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018; 24(13):3582-3592. PMC: 6226030. DOI: 10.1016/j.celrep.2018.08.079. View

16.

Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T . A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods. 2016; 84:111-127. DOI: 10.1016/j.vascn.2016.12.003. View

17.

Zhao Z, He X, Han W, Chen X, Liu P, Zhao X . Genus Tetradium L.: A comprehensive review on traditional uses, phytochemistry, and pharmacological activities. J Ethnopharmacol. 2018; 231:337-354. DOI: 10.1016/j.jep.2018.11.035. View

18.

Mirams G, Cui Y, Sher A, Fink M, Cooper J, Heath B . Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res. 2011; 91(1):53-61. PMC: 3112019. DOI: 10.1093/cvr/cvr044. View

19.

Dutta S, Chang K, Beattie K, Sheng J, Tran P, Wu W . Optimization of an Cardiac Cell Model for Proarrhythmia Risk Assessment. Front Physiol. 2017; 8:616. PMC: 5572155. DOI: 10.3389/fphys.2017.00616. View

20.

Strauss D, Gintant G, Li Z, Wu W, Blinova K, Vicente J . Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting. Ther Innov Regul Sci. 2018; 53(4):519-525. DOI: 10.1177/2168479018795117. View